1. Home
  2. SCYX vs GAUZ Comparison

SCYX vs GAUZ Comparison

Compare SCYX & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.67

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Logo Gauzy Ltd. Ordinary Shares

GAUZ

Gauzy Ltd. Ordinary Shares

HOLD

Current Price

$0.98

Market Cap

22.5M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
GAUZ
Founded
1999
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
22.5M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
SCYX
GAUZ
Price
$0.67
$0.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$11.50
AVG Volume (30 Days)
408.0K
421.6K
Earning Date
11-05-2025
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,932,000.00
$96,810,000.00
Revenue This Year
$167.73
$22.59
Revenue Next Year
$290.78
$47.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.87
52 Week Low
$0.57
$0.95
52 Week High
$1.31
$13.00

Technical Indicators

Market Signals
Indicator
SCYX
GAUZ
Relative Strength Index (RSI) 59.59 33.86
Support Level $0.58 $1.17
Resistance Level $0.64 $1.39
Average True Range (ATR) 0.03 0.18
MACD 0.01 0.08
Stochastic Oscillator 91.33 2.07

Price Performance

Historical Comparison
SCYX
GAUZ

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: